Oncogenic Wnt3a expression as an estimable prognostic marker for hepatocellular carcinoma

Table 3 Clinicopathological characteristics of high Wnt3a expression in 80 hepatocellular carcinoma patients

Groups	Patients, n	% of total	Wnt3a high expression, n	% of total	χ2	P value
Differentiation					20.211	< 0.001
Poor	34	42.50	31	91.18
Moderate	41	51.25	26	63.41
Well	5	6.25	0	0.00
Tumor number					0.976	0.323
Single	64	80.00	44	68.75
Multiple	16	20.00	13	81.25
Liver cirrhosis					8.467	0.004
Absent	29	36.25	15	51.72
Present	51	63.75	42	82.35
HBV infection					12.957	< 0.001
Absent	15	18.75	5	33.33
Present	65	81.25	52	80.00
Periportal embolus					3.557	0.059
Absent	9	11.25	4	44.44
Present	71	88.75	53	74.65
AFP (ng/mL)					1.020	0.313
< 400	52	65.00	39	75.00
≥ 400	28	35.00	18	64.28
TNM staging					22.960	< 0.001
I-II	36	45.00	16	44.44
III-IV	44	55.00	41	93.18
Five-year survival					15.469	< 0.001
Yes	32	40.00	15	46.88
No	48	60.00	42	87.50

HBV: Hepatitis B virus; AFP: α-fetoprotein; TNM: Tumor-node-metastasis.